Evidence map›Paper›PMID 30363524›Full record

ReviewTranslational andrology and urology2018

Entering an era of radiogenomics in prostate cancer risk stratification.

Nachiketh Soodana-Prakash, Radka Stoyanova, Abhishek Bhat, Maria C Velasquez, Omer E Kineish, Alan Pollack, Dipen J Parekh, Sanoj Punnen

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Translational andrology and urology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Review
  3. Review
  4. Review
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Nachiketh Soodana-PrakashDepartment of Urology, University of Miami, Miami, FL, USA.
Radka StoyanovaSylvester Comprehensive Cancer Center, University of Miami, Miami, FL, USA.
Abhishek BhatDepartment of Urology, University of Miami, Miami, FL, USA.
Maria C VelasquezDepartment of Urology, University of Miami, Miami, FL, USA.
Omer E KineishDepartment of Urology, University of Miami, Miami, FL, USA.
Alan PollackSylvester Comprehensive Cancer Center, University of Miami, Miami, FL, USA.
Dipen J ParekhDepartment of Urology, University of Miami, Miami, FL, USA.
Sanoj PunnenDepartment of Urology, University of Miami, Miami, FL, USA.

Funding

MRI Imaging and Genetic Signatures to Manage Prostate Cancer OverdiagnosisR01CA189295 · NCI · UNIVERSITY OF MIAMI SCHOOL OF MEDICINE · PI POLLACK, ALAN · 2014 to 2018
$3.2M
(PQC4) Habitats in Prostate CancerR01CA190105 · NCI · H. LEE MOFFITT CANCER CTR & RES INST · PI BALAGURUNATHAN, YOGANAND, GILLIES, ROBERT J. · 2014 to 2017
$2.8M
NCI NIH HHS R01 CA189295NCI NIH HHS R01 CA190105
6 · The paper itself

Abstract

Radiogenomics is a field that amalgamates data from genomics and imaging techniques in order to derive clinically meaningful trends. In this article, we discuss the importance of prostate cancer risk classification and how data derived from genomic testing and multi-parametric magnetic resonance imaging (mpMRI) can be integrated into clinical decision-making processes with a focus on active surveillance (AS). Finally, we describe an ongoing prospective trial (Miami MAST trial) which incorporates imaging (mpMRI) and radiomics data in patients who are on AS for prostate cancer.

Indexed as

genomics assayspersonalized informationprostate cancerRadiogenomicsrisk stratification

Identifiers

PMID30363524
PMCPMC6178317

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.